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Background: Human milk lactadherin protects 
breastfed infants against symptomatic rotavirus 
infections. 
Results: A 20 aa peptide (namely pDGE-RGD) 
derived from equine lactahderin inhibits human 
rotavirus infectivity.  
Conclusion: pDGE-RGD interacts specifically 
with α2β1 integrin, thus hindering the rotavirus 
cell-attachment process. 
Significance: The discovery of the pDGE-RGD 
peptide may prove useful in the development of 
inhibitors of receptor recognition by rotavirus 
or other integrin-using viruses. 
 
ABSTRACT 
Human rotavirus is the leading cause of 
severe gastroenteritis in infants and children 
under the age of five years in both developed 
and developing countries. Human 
lactadherin, a milk-fat globule membrane 
(MFGM) glycoprotein, inhibits human 
rotavirus infection in vitro, whereas bovine 
lactadherin is not active. Moreover, it 
protects breastfed infants against 
symptomatic rotavirus infections. To explore 
the potential antiviral activity of lactadherin 
sourced by equines we undertook a 
proteomic analysis of MFGM proteins from 
donkey milk and elucidated its amino acid 
sequence. Alignment of the human, bovine 
and donkey lactadherin sequences revealed 
the presence of an Asp-Gly-Glu (DGE) α2β1 
integrin-binding motif in the N-terminal 
domain of donkey sequence only. Since 
integrin α2β1 plays a critical role during early 
steps of rotavirus host cell adhesion, we 
tested a mini-library of donkey lactadherin-
derived peptides containing DGE sequence 
for anti-rotavirus activity. A 20 amino acid 
peptide containing both DGE and RGD 
motifs (named pDGE-RGD) showed the 
greatest activity, and its mechanism of 
antiviral action was characterised: pDGE-
RGD binds to integrin α2β1 by means of DGE 
motif and inhibits rotavirus attachment to 
the cell surface. These findings suggest the 
potential anti-rotavirus activity of equine 
lactadherin and support the feasibility of 
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developing an anti-rotavirus peptide that 
acts by hindering virus-receptor binding. 
 
Human rotavirus is a double-stranded RNA 
virus belonging to the Reoviridae family. It is 
transmitted by the faecal-oral route, causing 
severe gastroenteritis in infants and children 
under the age of five years in both developed 
and developing countries, although mortality 
occurs mainly in developing countries. As a 
result of rotavirus infection, 114 million 
episodes of diarrhea, 25 million clinic visits, 2.4 
million hospital admissions, and more than 
500,000 deaths in children up to age 5 occur 
worldwide annually (1). Groups at increased 
risk for rotavirus infection include children who 
are hospitalized or in community care centers 
and undernourished and/or immunodeficient 
children (2). Moreover, since exclusive breast-
feeding was found to be associated with a lower 
incidence of rotavirus gastroenteritis (3-6), non-
exclusively breastfed children are considered an 
additional group more vulnerable to rotavirus 
infections. The mature virion is a triple-layered 
particle of about 100 nm in diameter: the most 
external layer is comprised of two viral proteins 
(VP), VP7 (~34 kDa) and VP4 (87 kDa) (7, 8) 
with VP4 being the major determinant of 
tropism and receptor binding (9-12). Trimeric 
spikes of VP4 are anchored into the 
intermediate VP6 layer, while the trimeric 
calcium-binding protein VP7 covers the virion 
surface, locking VP4 spikes into place. The 
proteolytic cleavage of VP4 by trypsin is 
essential for optimum rotavirus infectivity and 
produces two subunits, VP5* (60 kDa) and 
VP8* (28 kDa), which remain associated with 
the virion (13-15). Initial cell attachment by 
rotaviruses is mediated by VP8* binding to host 
cell glycans (16). Infection of permissive cells 
by many rotaviruses, including human (e.g. Wa 
and K8), monkey (RRV and SA11), and bovine 
(NCDV) strains, also depends on virus binding 
to particular integrins, a family of cell surface 
proteins that recognize extracellular matrix 
proteins (e.g., collagen), cell surface ligands 
(e.g., Vascular cell adhesion molecule-1)(17), 
growth factors (e.g., Fibroblast growth factor-
1)( 18), and viral proteins (e.g., rotavirus). 
VP5* recognition of the collagen-binding α2β1 
integrin is a key event in rotavirus binding and 
entry into cells which is followed by the 
interaction of VP7 with integrins αxβ2, α4β1 
and αvβ3 (9, 19-24). The VP5* of almost all 
group A rotaviruses contain the Asp–Gly–Glu 
(DGE) sequence at aa 308–310, a motif that has 
been implicated in α2β1 recognition by type I 
collagen (17). Mutation of the putative α2β1 
ligand sequence DGE abrogates binding of 
truncated VP5* to the integrin α2 subunit I 
domain (α2I) and VP5* competition with RRV 
cell binding and infectivity (9, 25). In addition, 
DGE-containing peptides such as Asp–Gly–
Glu–Ala (DGEA) specifically inhibit rotavirus-
cell binding and infection mediated by α2β1 (9, 
20, 21, 25). Binding by infectious monkey 
(SA11, RRV) and human (Wa) rotaviruses to 
recombinant α2β1 expressed on K562 cells was 
specifically inhibited by DG-containing 
peptides and a function-blocking antibody to 
the α2I domain (9, 21, 23). Therefore, the 
interaction of rotavirus with α2β1 integrin can 
be considered a target for the development of 
antiviral agents aimed at preventing or reducing 
rotavirus infection. 
Bioactive components in milk are an important 
research focus (26). In vitro, lactadherin, a 
milk-fat globule membrane (MFGM) 
glycoprotein, inhibits rotavirus infection when 
sourced from humans, whereas bovine 
lactadherin is not active against human 
rotavirus (27). Moreover, it has been reported 
that human milk lactadherin protects breastfed 
infants against symptomatic rotavirus infections 
(6). Lactadherins isolated from different animal 
species are characterised by two N-terminal 
epidermal growth factor (EGF)-like domains, 
the second of which contains an Arg-Gly-Asp 
(RGD) integrin-binding motif that engages 
αvβ3/5 integrins and two C-terminal 
Discoidin/F5/8C domain repeats (28). Bovine 
lactadherin consists of 427 amino acid residues, 
including an N-terminal signal sequence of 18 
amino acids that is cleaved during intra-cellular 
processing. In contrast, human lactadherin is a 
protein of 387 amino acids including an N-
terminal signal sequence of 23 residues. When 
separated by two-dimensional electrophoresis 
(2DE), each of these proteins shows an 
apparent molecular mass above the theoretical 
value, with the difference due to glycosylation 
(29-31). MFGM-associated proteins from water 
buffalo, sheep and horse also have been 
analysed (32-34). Comparative species-to-
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species structural studies among MFGM 
proteins showed high variation especially for 
lactadherin (35). It is proposed that these 
differences could explain the divergent effects 
of bovine and human lactadherin on human 
rotavirus infection. In order to test if the lack of 
rotavirus inhibition by bovine lactadherin is 
atypical or represents a shared property 
amongst lactadherins of related domesticated 
animals we undertook a proteomic analysis of 
MFGM proteins from equine milk and 
elucidated the amino acid sequence of donkey 
lactadherin. Alignment of the human, bovine 
and donkey lactadherin sequences revealed the 
presence of a DGE integrin-binding sequence 
motif in the donkey sequence only, suggesting a 
potential antirotavirus activity. To test this 
hypothesis, a mini-library of donkey 
lactadherin-derived peptides containing DGE 
sequence was tested for anti-rotavirus activity. 
A 20 amino acid peptide containing both DGE 
and RGD sequence showed the greatest 
activity, and its mechanism of antiviral action 
was characterised. These findings shed light on 
the mechanisms of equine lactadherin inhibition 
of rotavirus infection and support the feasibility 
of developing an anti-rotavirus peptide that acts 
through inhibition of virus-receptor binding. 
 
 
EXPERIMENTAL PROCEDURES 
Preparation of fat globules from donkey milk - 
Milk was collected from several donkeys at a 
single farm. Protease inhibitors (Complete; 
Roche Diagnostics, Basle, Switzerland) were 
added and the milk immediately stored at - 
20°C. Thawed milk was centrifuged at 5000×g 
for 30 min at 10°C and the pellet discarded. The 
cream layer and skimmed milk were 
centrifuged at 189,000×g for 70 min at 6°C. Fat 
globules were recovered in the supernatant and 
washed three times with 0.9% (w/v) NaCl. 
 
Sample protein preparation and 2-DE - 
Washed fat globules were incubated at 4°C 
overnight in 20 mM Tris-HCl pH 8.6 
containing 1% (w/v) ASB-14, 1% (v/v) Triton 
X-100, 7 M urea and 2 M thiourea to extract the 
proteins associated with fat globule membranes. 
After centrifugation at 18,400×g for 10 min at 
10°C the floating cream layer was discarded. 
Proteins were precipitated from the supernatant 
with methanol and chloroform, as described 
previously (36). Pellets containing proteins 
were solubilized in 20 mM Tris-HCl pH8.6 
containing 7 M urea, 2 M thiourea, 1% (w/v) 
ASB-14, 1% (v/v) DTT and 0.5% (v/v) IPG 
buffer. Total protein was quantified using the 2-
D Quant kit (GE Healthcare). Extracted 
proteins (200 µg) were loaded onto 13 cm pH 
3-10 NLIPG Strips (GE Healthcare Bio-
Sciences Corp, USA). IEF was carried out on 
an IPGphor unit (GE Healthcare) at 20°C and 
8000 V for a total of 70,000 Vhr. Strips were 
incubated at room temperature in 50mM Tris-
HCl pH 8.6 containing 6 M urea, 30% (v/v) 
glycerol, 2% (w/v) SDS, enriched with 2% 
(w/v) DTT for 20 min and afterwards with 
4.5% (w/v) iodoacetamide for 20 min. SDS 
polyacrylamide gel electrophoresis was carried 
out on homogeneous running gels with 11.7% 
total acrylamide concentration and a 2.6% 
grade of cross-linking (Ettan DALT II system, 
GE Healthcare) at 400 V and 50 mA per gel for 
approx. 3 h. Gels were stained using the 
Processor Plus (GE Healthcare) with Blue 
Coomassie Colloidal stain (37) and scanned 
with a GS-800 Densitometer (Biorad 
Laboratories Inc., Hercules, CA, USA). 
 
Enzymatic digestion of proteins - In-gel 
Multiple Enzymatic Digestion on selected 2-DE 
spots was performed according to the published 
method (38). Briefly, excised spots were 
destained for 2 h in 40% (v/v) ethanol 
containing 50 mM NH4HCO3, dehydrated 3 
times (10 min each) in acetonitrile and dried in 
a vacuum concentrator for 30 min. Rehydration 
was performed at room temperature for 5 min 
with 5 µl of 75 ng/µl trypsin in 25 mM 
NH4HCO3 (Promega Corp., Madison, WI), 5 µl 
of 75 ng/µl Asp-N solution (Sigma), or 5 µl of 
75 ng/µl of chymotrypsin in 25 mM NH4HCO3 
(Sigma). Digestion continued at 37°C. Asp-N 
peptides were collected after 2 h of digestion 
and submitted to mass spectrometry (MS). 
Trypsin and chymotrypsin digestions were 
performed overnight after the addition of 15 µl 
of 25 mM NH4HCO3/10% (v/v) acetonitrile. 
These supernatants were collected and 
submitted for MS analysis on the following day 
 
Mass spectrometric analysis - For MALDI-
TOF mass spectrometry, 0.5 µl of each peptide 
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mixture was applied to a target disk and 
allowed to air-dry. Subsequently, 0.5 µl of 
matrix solution (1% (w/v) α-cyano-
4hydroxycinnamic acid in 30% (v/v) 
acetonitrile and 0.1% (v/v) trifluoroacetic acid 
were applied to the dried sample and dried 
under vacuum. Spectra were collected on a 
Ultraflex II MALDI-TOF-TOF (Bruker 
Daltonik GmbH, Germany). The reported mass 
spectra are the result of signals of 
approximately 800 laser shots. The spectra were 
externally calibrated using the standard 
calibration mixture from Bruker Daltonik 
(GmbH, Germany). Manual/visual estimation 
of the mass spectra was performed using Flex 
Analysis software (Bruker Daltonik GmbH, 
Germany). For LC-MS/MS experiments an 
Agilent’s 1100 Series liquid chromatography 
and LC/MSD XCT series ion trap mass 
spectrometer equipped with nano-ESI source 
were used. Peptide mixtures were separated on 
a RP C18 column (Zorbax 300SB-C18 3.5 µm 
150x0.075 mm) (CPS) equilibrated with 0.1% 
(v/v) formic acid in water. Peptides were eluted 
over 55 min with a linear gradient of 5%-70% 
(v/v) of 0.5% water/0.1% formic acid in 
acetonitrile. The flow rate was 300 nl/min. The 
mass spectrometer was operated in positive ion 
mode. Data were processed using DataAnalysis 
software (Agilent Technologies, Santa Clara, 
U.S.). 
 
Spectra interpretation - For Peptide Mass 
Fingerprinting (PMF) identification, the MS-Fit 
software package in ProteinProspector version 
5.10.9 (http://prospector.ucsf.edu/) was used for 
spectra interpretation (39). Data were searched 
against the Horse database 
UniProtKB.2012.03.21. 
The parameters used for the search were: S-
carbamidomethyl derivate on cysteine as fixed 
modification, oxidation on methionine as 
variable modification and two missed cleavage 
sites for trypsin digestion. The peptide mass 
tolerance was 30 ppm.  
The LC-MS/MS and MALDI-TOF/TOF spectra 
were analyzed using the MASCOT MS/MS 
Ions Search engine 
(http://www.matrixscience.com/) against the 
UniProtKB.2012.03.21database.The parameters 
used for the search were: S-carbamidomethyl 
derivate on cysteine as fixed modification, 
oxidation on methionine as variable 
modification, two missed cleavage sites for 
each enzymatic digestionand default selection 
of charge states ions (+2, +3). The peptide mass 
tolerance was set to 0.6 Da and the fragment 
mass tolerance to 0.8 Da. Protein hits were 
validated if the protein scores were above the 
MASCOT default significance threshold 
(p≤0.05), and a minimum of two unique 
peptides matched. 
 
N-terminal sequencing - Spots were passively 
eluted from gels as described elsewhere (40) 
and the membrane analyzed by direct micro 
sequencing on a Procise 492 protein sequencer 
(Applied Biosystems, CA, USA). All chemicals 
were purchased from Applied Biosystems. 
 
Cell lines and viruses - African green monkey 
kidney epithelial cells (MA104) and human 
epithelial colorectal adenocarcinoma cells 
(Caco-2) were propagated, respectively, in 
Eagle's Minimum Essential Medium (MEM) 
and Dulbecco’s Modified Eagle Medium 
(DMEM; Sigma, St. Louis, MO). Both media 
were supplemented with 1% (v/v) Zell Shield 
(Minerva Biolabs, Berlin, Germany) and heat 
inactivated, 10% (v/v) fetal bovine serum 
(Sigma). 
Chinese hamster ovary (CHO-K1) cells were 
cultured in High Glucose DMEM (PAA, 4061 
Pasching, Austria) supplemented as above. 
The derivation of CHO K1 cell transfectants 
expressing human α2 integrin subunit (CHO 
α2) or the PBJ-1 empty vector (CHO K1 PBJ-1) 
has been described previously (41-45). CHO 
cell transfectants were grown as for the parental 
cell line, except that G418 sulfate (Sigma) at 
0.1 µg/ml to 0.8 µg/ml was included in the 
growth medium. 
Human rotavirus strain Wa was obtained from 
the ATCC; the origin of porcine rotavirus P9 
G3 strain CRW-8 has been described 
previously (46).  Wa and CRW-8 infectivity 
was activated with 5 µg/ml of porcine 
pancreatic trypsin type IX (Sigma) for 30 min 
at 37°C and propagated in MA104 cells in 
MEM containing 0.5 µg/ml trypsin as described 
previously (47).  
 
Antibodies - Mouse monoclonal antibodies 
(MAb) directed to human rotavirus VP6 (0036), 
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α2β1 integrin (AK7) and αvβ3 integrin 
(LM609) were purchased from Covalab 
(Villeurbanne, France), Abcam (Cambridge, 
UK) and Millipore (Molsheim, France), 
respectively. 
 
Peptides - Synthetic peptides, pRGD-Hu 
(EVRGDVFP), pRGD-Bo (SHRGDVFI) 
(derived from human and bovine lactadherin, 
respectively), pRGD-Eq (SHRGDVFT), pDGE 
(QNDGECHV) (derived from equine 
lactadherin), pRGE (SHRGEVFT), pAGE 
(QNAGECHV) were purchased from 
Eurogentec (Liege, Belgium). Synthetic 
peptides pDGE-RGDmut1 
(NNDGECHVIDDSHRGDVFTQ), pDGE-
RGDmut2 (QNDGECHVIDDSDRGDVFTQ), 
pDGE-RGDmut3 
(QNDGECHVIDDSHRGDVFSQ), pAGE-
RGD (QNAGECHVIDDSHRGDVFTQ), 
pDGE-RGE (QNDGECHVIDDSHRGEVFTQ) 
were purchased from Proteogenix (Valparc, 
France). pDGE-RGD19 
(NDGECHVIDDSHRGDVFTQ) and pDGEA 
(DGEA) were purchased from the PolyPeptide 
Group (Strasbourg, France). pAGE-RGE 
(QNAGECHVIDDSHRGEVFQT) was 
purchased from the CASLO Laboratory 
(Technical University of Denmark, Lyngby, 
Denmark). 
pDGE-RGD peptide 
(QNDGECHVIDDSHRGDVFTQ), derived 
from equine lactadherin, was purchased from 
Eurogentec, PolyPeptide Group, Proteogenix 
and CASLO Laboratory. 
Biotinylated peptides Biot-pDGE (Biotin-
QNDGECHV), Biot-pAGE (Biotin-
QNAGECHV) and Biot-pDGE-RGD (Biotin-
QNDGECHVIDDSHRGDVFTQ) were 
purchased from Proteogenix. MALDI-TOF 
mass spectrometry analysis confirmed that 
pDGE-RGD, the peptide of major interest for 
this study, was soluble and monomeric (data 
not shown). 
Rotavirus infectivity assays - Peptide blockade 
of virus infectivity was determined by focus 
reduction assay using confluent MA104 cell 
monolayers in 96-well trays, as described 
previously (21). Unless otherwise stated, cells 
were treated for 1 h at 37°C with peptides at 
0.01 µM to 500 µM in serum-free medium prior 
to virus addition. Rotavirus infection was 
performed at a multiplicity of infection (MOI) 
of 0.02, unless otherwise indicated, for 1 h at 
37°C, in presence of the peptide unless 
otherwise stated. Infected cells were washed 
with serum-free medium and incubated in this 
medium at 37°C in a humidified incubator in 
5% (vol/vol) CO2–95% (vol/vol) air. In some 
experiments (as indicated), peptide pDGE-RGD 
was included with these washed, infected cells 
for the duration of their incubation. After 16 h 
of incubation, infected cells were fixed with 
cold acetone-methanol (50:50), and viral titers 
determined by indirect immunostaining, by 
using UltraTech HRP Streptavidin-Biotin 
Detection System (Beckman Coulter) according 
to the manufacturer's instructions. Peptide 
blockade of viral infectivity is expressed as 
mean % ± SD. Where possible, anti-viral 
effective concentration (IC50) values were 
calculated by regression analysis using the 
dose-response curves generated from the 
experimental data, using PRISM 4 (GraphPad 
Software, San Diego, CA, U.S.A.). IC50 values 
were compared using the sum-of-squares F test. 
 
Assay of virus yield - To test the ability of 
pDGE-RGD to inhibit multiple cycles of viral 
replication, confluent MA104 cells in 24-well 
trays were infected with trypsin-activated Wa 
rotavirus (MOI=0.02) for 1 h at 37°C and 
washed as above. Cells were incubated in 
medium supplemented with 0.5 µg/ml porcine 
trypsin and 30, 100 or 300 µM pDGE-RGD, 
with fresh pDGE-RGD added to peptide-treated 
wells at 16 h after infection and at later fixed 
intervals, and an equal volume of medium 
added to untreated controls at these times. 
Infected cells and cell supernatants were 
harvested at 48 h post infection and virus titers 
determined by indirect immunostaining of 
MA104 cell monolayers inoculated with serial 
dilutions of the samples. The assay was 
performed in triplicate.  
 
Rotavirus-cell binding assay - Confluent 
MA104 cell monolayers in 24-well trays were 
washed, incubated with peptides or antibodies 
for 1 h at 37°C and cooled on ice for 20 min in 
the continuing presence of peptides or 
antibodies. Trypsin-activated virus, which had 
been cooled to 4°C, was allowed to attach to 
cells on ice for 1 h (MOI=3) in presence of 
Equine Lactadherin Peptides Inhibit Human Rotavirus Infection 
 
6 
 
peptides or antibodies. Cells were washed with 
cold MEM; cold MEM was added. Cells were 
subjected to two rounds of freeze-thawing, 
incubated at 37°C for 30 min with 10 µg/ml 
porcine trypsin to release bound virus, and the 
lysate clarified by low speed centrifugation for 
10 min. Cell-bound virus titers were determined 
by indirect immunostaining as above.  
 
Rotavirus-cell entry assay - Confluent MA104 
cell monolayers in 96-well trays were washed 
twice with MEM and cooled on ice for 20 min. 
Trypsin-activated virus, which had been cooled 
to 4°C, was adsorbed to cells on ice for 1 h at 
4°C (MOI=0.02). Peptide pDGE-RGD was 
added to washed cells at 0.01 µM to 500 µM 
for 1 h at 37°C. Rotavirus entry was stopped by 
removal of surface-bound virions with two 
quick washes with 3 mM EGTA in PBS, which 
removes the virion outer capsid (48, 49). Cells 
were incubated in MEM for 16 h at 37°C, fixed, 
stained and titers determined as described 
above for the infectivity assay. 
 
Virucidal assay - Trypsin-activated Wa 
rotavirus was reacted with 100 µM pDGE-RGD 
peptide or diluent for 1 h at 37°C, then titrated. 
Viral yields were determined by indirect 
immunostaining, by counting the number of 
infectious foci at 1:1024, 1:2048 and 1:4096 
dilutions. 
 
Peptide-cell binding assay - Confluent CHO K1 
and CHO α2 cells in 96-well trays were washed 
twice with DMEM containing 1% (w/v) BSA 
and incubated for 1 h at 37°C with 0.3 µM, 3 
µM or 30 µM Biotin-pDGE, Biotin-pAGE or 
Biotin-pDGE-RGD peptides in the same 
DMEM diluent. Washed cells were incubated 
with streptavidin-HRP (Beckman Coulter) for 
10 min at room temperature, washed twice with 
PBS and reacted with ABTS reagent 
(Thermoscientific, IL, U.S.A.) for 30 min at 
room temperature The reaction was stopped 
with PBS containing 5% (w/v) SDS and the 
absorbance determined at λ=405 nm.  
 
Cell viability assay - The cytotoxicity of 
peptide pDGE-RGD was assessed in MA104 
and CaCo2 cells seeded in 96-well plates at a 
density of 1.2×10
4
 cells/well. After 24 h of 
culture, cells were treated with peptide at 
0.0044 µM to 880 µM. Cell viability was 
determined 48 h later with the CellTiter 96 
Proliferation Assay kit (Promega, WI, USA) 
according to the manufacturer’s instructions. 
Absorbances were measured using a model 680 
microplate reader (Biorad) at 490 nm. Viability 
in treated cells was expressed as a percentage 
relative to cells incubated with culture medium 
alone. The 50% cytotoxic concentration (CC50) 
was determined using logarithmic viability 
curves. Where possible, a selectivity index (SI) 
was calculated by dividing the CC50 by the IC50 
value. 
 
Statistical analysis - One-way analysis of 
variance (ANOVA), in some cases followed by 
the Bonferroni test, was used to assess the 
statistical significance of differences in virus 
titers and absorbance data. Significance was set 
at the 95% level.  
 
RESULTS 
Proteomic analysis and protein sequencing 
indicate the presence of two putative integrin 
ligand motifs in equine lactadherin - The 2-DE 
map of donkey milk fat globule membrane 
proteins was determined (Figure 1). The 2DE 
map showed a pattern very similar to that 
previously published for horse MFGM proteins, 
where lactadherin was the major protein and 
was identified in several spots at different 
molecular masses (34). The spots 1 to 4, 
corresponding to the molecular masses of horse 
lactadherin, were excised and the proteins 
identified by MALDI-TOF MS and PMF as the 
horse milk fat globule-EGF factor 8 splice 
variant, also known as horse lactadherin (Table 
1). To understand the nature of the difference 
between the ~45 kDa and ~50 kDa proteins, 
their N-terminal amino acid sequences were 
determined (Table 2). The sequences of 
proteins 1 and 2 matched the N-terminal amino 
acid sequence of horse lactadherin (UniProt 
F7B0S3) with an identity of ≥95%. Proteins 3 
and 4 corresponded to the same horse 
lactadherin sequence, commencing from the 
amino acid residue at position 44. As the 45 
kDa form was most similar to the human 
counterpart, its amino acid sequence was 
examined further. The results of multiple 
enzymatic digestions of this 45 kDa protein 
with trypsin, Asp-N and chymotrypsin, 
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followed by MALDI-TOF/TOF and nano 
LC−ESI MS/MS analyses (Table 3), together 
with the N-terminal amino acid sequence, gave 
an (almost) complete coverage of the sequence 
of this form of donkey lactadherin (Figure 2). 
The sequence was submitted to UniProt 
database and the accession number C0HJR4 
was assigned.  
The sequence alignment of this equine (EQ) 
lactadherin with the bovine (BO) and human 
(HU) lactadherins revealed some very 
interesting features in the N-terminal domains 
(Figure 3). An RGD motif is conserved in the 
three proteins, being present at amino acid 
residues 23 to 25 in equine and human 
lactadherin, and at residues 67 to 69 in bovine 
lactadherin. RGD is an integrin-binding motif 
that engages αvβ3, αvβ5, α3β1 and α5β1 integrins 
to facilitate cell adhesion. Surprisingly, the 
equine lacthaderin was shown to contain an 
additional integrin binding motif, the DGE 
sequence that can specifically bind the α2β1 
integrin, which is present at residues 12 to 14. 
 
Functional roles of the equine lactadherin RGD 
and DGE sequences in inhibition of rotavirus 
infection - In order to assess the importance of 
the RGD sequence (shared by human, bovine 
and equine lactadherin) and the DGE motif 
(present in equine lactadherin only) for 
inhibition of rotaviral infection, the effect on 
Wa infection of cellular treatment with the 8 
amino acid peptides pRGD-Hu, pRGD-Bo, 
pRGD-Eq, and pDGE was determined. These 
human, bovine and equine RGD-peptides 
inhibited Wa infection of MA104 cells in a 
dose-dependent fashion to maxima at 500 µM 
of 57%, 50% and 47% respectively (Figure 
4A). In contrast, MA104 cell treatment with an 
8 amino acid RGE peptide harboring a single 
amino acid substitution (D→E) known to 
inhibit the ability of RGD triplet to bind 
integrin (pRGE), had no effect on virus 
infectivity even at high concentrations (Figure 
4A). Notably, the DGE-containing peptide 
pDGE derived from equine lactadherin 
inhibited Wa infectivity to maximum of 84% 
(Figure 4B), making it possible to assess its 
IC50 at 17 µM (Table 4). As expected, an AGE 
peptide (pAGE), despite its ability to inhibit 
rotaviral infectivity to maximum of 80%, 
showed a significantly higher IC50 (257 µM) 
than pDGE (p<0.0001; Table 4).  As positive 
control, we tested the Type I collagen-derived 
peptide Asp-Gly-Glu-Ala  (pDGEA); this α2β1 
integrin ligand showed an antiviral activity 
comparable to the one previously reported (21), 
as depicted in Figure 4B.  
 
A 20 amino acid region of equine lactadherin 
has elevated specific anti-rotaviral activity in 
epithelial cell cultures that depends on its RGD 
and DGE sequences - Interestingly, the 20 
amino acid peptide pDGE-RGD, corresponding 
to amino acids 10 to 29 of equine lactadherin 
and harboring both the RGD and DGE motifs, 
showed the highest anti-rotaviral efficacy 
(IC50=4.4 µM; Table 4). pDGE-RGD was 
therefore selected as the lead compound for 
further studies. Of note, the pDGE-RGD 
peptide maintained a significant (p<0.05) 
inhibitory activity against high MOIs of Wa 
(Figure 4C). The stage of the rotavirus 
replication cycle inhibited by peptide pDGE-
RGD was examined. Peptide addition 1 h 
before or immediately after infection did not 
inhibit Wa infectivity. The greatest infectivity 
inhibition was achieved when the peptide was 
added during infection (Figure 5), as performed 
in the experiments described above and the 
following studies. To assess the role played by 
each motif in inhibition of rotavirus infectivity, 
the antiviral activity of several mutant peptides 
derived from pRGD-DGE that harbored 
mutations in DGE (D→A, pAGE-RGD), RGD 
(D→E, pDGE-RGE) or both triplets (pAGE-
RGE) was tested. These peptides failed to show 
any antiviral activity even at high 
concentrations, demonstrating the importance 
of these motifs for anti-rotavirus activity (Table 
4). In contrast, peptides with single amino acid 
substitutions outside these functional groups, 
namely pDGE-RGDmut1, pDGE-RGDmut2 
and pDGE-RGDmut3, retained the ability to 
inhibit Wa infection (Table 4), at levels 
comparable to those of pDGE-RGD. No 
significant difference was seen between the IC50 
of pDGE-RGD and these peptides with amino 
acid substitutions outside the DGE and RGD 
functional groups (p>0.05). The antiviral 
efficacy of pDGE-RGD and its AGE- and 
RGE-mutants was also evaluated in the Caco-2 
intestinal cell line (Table 5). While pDGE-RGD 
showed antiviral activity in Caco-2 cells 
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(IC50=8.8 µM) comparable to that in MA104 
cells, pDGE-RGE, pAGE-RGD, and pAGE-
RGE exhibited a significant loss of activity 
(p<0.0001). Interestingly, these Caco-2 cell 
studies identified significant differences in 
antiviral activity between these three peptides 
(0.002<p<0.0194), with pDGE-RGE showing a 
lower IC50 (46 µM) than pAGE-RGD (IC50=101 
µM) and pAGE-RGE (IC50=152 µM). This 
suggests that the DGE sequence plays a major 
role in the process leading to rotavirus 
inhibition. In order to rule out any non-specific 
effect due to loss of cell viability, MTS cell 
viability assays were performed after incubation 
of Wa-infected and control MA104 and Caco-2 
cell cultures for 72 h with a range of peptide 
concentrations. The tested peptides did not 
impair cell viability at any concentration tested 
on MA104 cells, showing a 50% cytotoxic 
concentration (CC50) of >880 µM (Tables 4 and 
5). In Caco-2 cells, the pDGE-RGD CC50 was 
945 µM. CC50 values were used to calculate the 
selectivity index of pDGE-RGD, which was 
>100 for both cell lines (Tables 4 and 5). 
 
Infectious rotavirus yield is reduced by the 20 
amino acid lactadherin peptide - The antiviral 
activity of pDGE-RGD was evaluated in a virus 
yield assay, a more a stringent test that allows 
multiple cycles of viral replication to occur 
before measuring the titer of infectious virus 
produced. Wa rotavirus yield was reduced in a 
dose-dependent manner in cells treated with 
100 µM or 300 µM pDGE-RGD (p<0.05), 
showing 50% and 84% inhibition, respectively 
(Figure 6). 
 
The 20 amino acid lactadherin peptide binds 
α2β1 integrin in a DGE-dependent manner - The 
results described above suggested that pDGE-
RGD may inhibit rotavirus infectivity by 
binding the α2β1 integrin, thereby blocking viral 
binding to this cellular receptor. The ability of 
equine lactadherin peptides to specifically bind 
α2β1 was tested by treating CHO cells 
expressing surface α2β1 with biotinylated 
pDGE-RGD, pDGE and pAGE peptides. 
Peptides pDGE-RGD and pDGE bound to the 
surface of α2β1-expressing CHO cells in a dose-
dependent manner, whereas pAGE did not 
show this ability (Figure 7A). Peptide pDGE-
RGD bound to a greater extent than pDGE, as 
pDGE-RGD binding was significant greater 
than that of pDGE at 3 µM and 30 µM 
(0.01<p<0.02). In contrast, pDGE binding to 
the CHO parental cell line (CHO-K1) (Figure 
7B) was reduced compared to α2β1-expressing 
CHO cells at all concentrations tested 
(p<0.0006). No difference was detected 
between pDGE and pAGE binding to CHO-K1 
cells (p>0.05). Interestingly, substantial binding 
of pDGE-RGD to CHO-K1 cells was evident, 
indicating binding to cell surface component(s) 
other than α2β1. Consistently, at 30 μM pDGE-
RGD binding to the surface of α2β1-expressing 
CHO cells was significantly greater than to the 
parental cell line (p<0.05). 
 
The 20 amino acid lactadherin peptide 
preferentially inhibits rotavirus-cell attachment 
rather than entry, in a DGE-dependent manner 
- In order to evaluate the ability of pDGE-RGD 
to inhibit rotavirus-cell attachment we 
measured the titer of infectious Wa rotavirus 
particles attached to pDGE-RGD-treated and 
untreated MA104 cells. pDGE-RGD 
significantly reduced Wa binding by a 
maximum of 67% (p<0.0001), while pAGE-
RGE did not show any inhibitory activity 
(p>0.05; Figure 8A). As found previously (9), 
the AK7 MAb to integrin α2β1 reduced virus-
cell binding to maximum of 51% (p<0.05), 
whereas MAb LM609 to integrin αvβ3 had no 
significant effect (p>0.05) effect. In a control 
experiment, we tested the antiviral efficacy of 
pDGE-RGD against the integrin-independent 
rotavirus strain CRW-8. As expected, pDGE-
RGD did not inhibit CRW-8 infectivity at any 
concentration tested (Figure 8B). The effect of 
pDGE-RGD on viral entry also was 
investigated. This peptide significantly 
inhibited Wa rotavirus-cell entry only when 
added to cells at very high concentations i.e. 
300 µM or 500 µM (p<0.05; Figure 8C). In 
order to rule out any virucidal effect of pDGE-
RGD on rotavirus, Wa was exposed for 1 h to a 
pDGE-RGD concentration (100 µM) able to 
inhibit to 80% of Wa infectivity. The infectious 
titer of the pDGE-RGD-treated viral suspension 
was indistinguishable for that of the untreated 
control (p>0.05; Figure 8D). 
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DISCUSSION 
Many human and animal rotaviruses contain the 
Asp–Gly–Glu (DGE) sequence in VP8*, which 
is necessary for their usage of the α2β1 integrin 
to aid infection. In this study we have identified 
the putative integrin ligand motifs RGD and 
DGE in the N-terminal domain of donkey 
lactadherin. While the RGD motif is common 
to human, bovine and donkey lactadherins, the 
DGE motif is found only in the donkey 
sequence. Direct evaluation of the antiviral 
activity of donkey lactadherin would be of 
interest but has proven to be difficult. 
Difficulties arise when experiments to purify 
donkey lactadherin with the same methods used 
for the human and bovine proteins are 
attempted, since human and bovine milk 
contain a much higher amount of fat (approx 
3.5%) than donkey milk (approx. 0.3% ) from 
which only a very small amount of lactadherin 
could be recovered. For this reason we turned to 
the recombinant protein. We achieved bacterial 
expression of full-length donkey lactadherin, 
but the recombinant His-tagged protein was 
insoluble and could not be refolded 
(unpublished observations). This is consistent 
with the insolubility of milk-derived 
lactadherins, which are associated with the milk 
fat globule membrane (50). In any case, our 
main focus is on the development of rotavirus 
inhibitors based on derivative peptides, rather 
than analysing the full-length protein:  one main 
reason is that it is very unlikely that lactadherin 
molecules pass through the digestive tract intact 
- at least not in a relevant amount (e.g. we have 
easily digested donkey lactadherin with trypsin 
to solve their primary structure). Moreover, the 
ability of the DGE integrin binding domain to 
inhibit rotavirus replication can be addressed 
much more clearly working with small peptides 
rather than intact proteins, where the tertiary 
and eventually quaternary structure of the 
molecule could mask the biological activity of 
the inner part of some protein segment. To this 
end, we have demonstrated that peptides 
derived from donkey lactadherin, which contain 
the intact RGD and DGE sequences, 
specifically and effectively inhibit rotavirus 
infection at low µM levels. We selected a 20 
amino acid peptide derived from donkey 
lactadherin harboring the RGD and a DGE 
motif (pDGE-RGD) depending on its 
favourable SI and its ability to limit the 
production of viral progeny resulting from 
multiple cycles of viral replication.  The 
differences between MA104 and Caco-2 cells 
in the effectiveness of pDGE-RGD in 
preventing rotavirus cell infection parallel the 
data documented in a previous work (21), 
showing that a DGEA peptide was a less 
effective inhibitor of virus binding in Caco-2 
cells than in MA104 cells. The higher surface 
expression of α2β1 on Caco-2 cells than on 
MA104 cells (51) could explain these findings, 
as higher levels of peptide would be needed to 
block all available integrin sites that could bind 
virus.  
During our investigation of the functional roles 
of the equine lactadherin RGD and DGE 
sequences in inhibition of rotavirus infection, 
we found that pAGE-RGD, pDGE-RGE and 
pAGE-RGE mutant peptides lack antiviral 
activity on MA104 cells. Interestingly, we were 
able to discriminate a different contribution 
from the two motifs using Caco2 cells, with the 
DGE triplet being more critical than RGD in 
limiting Wa infectivity (IC50 of pAGE-RGD > 
IC50 of pDGE-RGE). These data - together with 
the fact that peptides harboring single amino 
acid substitutions outside these functional 
motifs retain their antiviral activity - suggest 
that both triplets are important for the inhibition 
of rotavirus infectivity. These specific 
substitutions (i.e. D→A for DGE and D→E for 
RGD) were chosen because an aspartate (D) or 
glutamate (E) residue is a critical feature of all 
integrin recognition sites (52). The amino acid 
substitution in the DGE motif (i.e. D→A) is 
known to alter the integrin α2β1 binding ability 
of VP5* (21, 24, 32), with D308 in VP5* being 
the major requirement for α2I binding by 
rotavirus. Overall, these results suggest that the 
antiviral activity of pDGE-RGD is dependent 
on its ability to interact with α2β1 integrin. This 
notion is supported further by the finding that 
infection by integrin-independent virus CRW-8 
was unaffected by pDGE-RGD. 
The demonstration of the antiviral efficacy of 
pDGE (an 8 aa peptide hardoring only the DGE 
triplet) extends data previously reported (21), 
which showed that individual peptide polymers 
containing the collagen–binding motif DGEA 
inhibit rotavirus infectivity by more than 60% 
in Caco-2 and MA104 cells and provided 
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additional evidence of the importance of α2β1 
in the rotavirus cell attachment and entry 
process. We also tested the antiviral efficacy of 
DGEA peptide in our experimental systems, 
confirming the efficacy previously reported 
against the Wa strain (21) and showing that 
pDGE has a greater inhibitory capacity. 
Notably, an 8 aa mutant peptide (pAGE) 
showed a significant antirotaviral activity only 
at high concentrations. Taken together, these 
results confirm that the antiviral activity of 
pDGE-RGD peptide is mostly dependent on the 
integrity of the DGE triplet. Nevertheless, 
pDGE shows a less effective antiviral activity 
than pDGE-RGD, suggesting that a second 
region of this peptide provides an additional 
contribution in inhibiting rotavirus infectivity. 
To this end, we showed that 8 aa RGD peptides 
(namely pRGD-Hu, pRGD-Bo and pRGD-Eq 
derived from human, bovine or equine 
lactadherin respectively) are endowed with a 
slight antiviral efficacy. Published studies 
provide evidence that rotavirus infectivity is not 
inhibited by RGD peptide, and function-
blocking antibodies to RGD-binding integrins 
do not inhibit rotavirus infection (20, 23, 53). 
No evidence for Wa binding to integrins via 
RGD is available. We speculate that the slight 
antiviral efficacy of RGD peptides may be due 
to an indirect effect on rotavirus cell binding, 
perhaps by anchoring pDGE-RGD peptide to 
the cell surface and sterically blocking Wa virus 
access to receptors.  
The results of the virucidal assay rule out the 
possiblity of a direct effect of peptide treatment 
on rotavirus particles, while the time of addition 
assays suggest that pDGE-RGD might function 
by hindering the attachment of the virus to the 
host cell. The results of rotavirus cell-binding 
experiments confirm this conclusion: the titer of 
infective particles attached on the surface of 
pDGE-RGD treated cells is significantly 
reduced compared with the untreated control. 
Moreover, pAGE-RGE peptide does not reduce 
the number of infectious particles attached to 
the cell surface, showing that this ability is 
strictly dependent on the integrity of the DGE 
or RGD sequences. Consistent with these 
considerations, we demonstrated that both 
pDGE and pDGE-RGD bind α2β1 integrin in a 
DGE-dependent manner, since pAGE does not 
interact with α2β1-expressing CHO-K1 cells. 
The pDGE and pDGE-RGD peptides interact in 
a dose-dependent manner with α2β1 expressed 
on the surface of CHO-K1 cells. Importantly, 
pDGE-RGD bound the cellular surface to a 
greater extent than pDGE, which parallels the 
higher antiviral activity of the longer peptide. 
Moreover, we show that pDGE-RGD (unlike 
pDGE) is able to interact with the surface of 
CHO-K1 parental cell line that does not express 
α2β1 on the cellular surface. This result 
suggests that pDGE-RGD interacts wih a 
second surface determinant, a clue that could 
explain the greater antiviral activity of pDGE-
RGD compared to pDGE. Of the known RGD-
binding integrins, CHO-K1 cells express α5β1 
and αvβ5, but not α3β1 or αvβ3 (54, 55). It is 
likely that pDGE-RGD binds α5β1 or αvβ5 on 
CHO-K1 cells and α2β1-expressing CHO-K1 
cells, as well as binding α2β1 on α2β1-
expressing CHO-K1 cells. The close proximity 
of the RGD and DGE motifs in pDGE-RGD is 
expected to preclude binding to both α2β1 and 
an RGD-recognising integrin simultaneously by 
a single peptide molecule. However, peptide 
anchorage to an RGD integrin like α5β1, which 
is abundant on CHO-K1 cells, could prevent 
virus access to α2β1 and possibly other 
receptors. Interestingly, rotavirus-cell entry 
experiments showed that pDGE-RGD is able to 
inhibit rotavirus infectivity when added after 
virus-cell attachment, even if only slightly and 
at high concentrations. One possibility is that 
high concentrations of pDGE-RGD could 
interfere with virus-cell attachment, even after 
it took place, by mediating detachment of part 
of the viral population from the cell surface. It 
is also possible that integrin-bound pDGE-RGD 
is endocytosed and inhibits virion conversion 
into the transcriptionally-active, double-layered 
particle, which for Wa has been proposed to 
occur during exit from late endosomes (56). 
Interestingly, Wa VP8* binds the GM1 
ganglioside, which can associate with integrins 
such as α5β1 and α2β1 in membrane 
microdomains (57, 58) and has been proposed 
to classify cargo for uptake and trafficking in 
late endosomes (59). Binding of pDGE-RGD to 
β1 integrins internalised in endosomes also 
might interfere with Wa access to the 
cytoplasm, which is essential for replication 
(60).  
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Overall, the information obtained in the present 
study indicates that a specific 20 aa peptide 
from the N-terminal domain of donkey 
lactadherin is able to block rotavirus cell-
adhesion and infectivity in a DGE-dependent 
manner. Previously reported data (21) show that 
polymerization increases the effectiveness of 
peptide polymers containing the collagen–
binding motif DGEA as rotavirus inhibitors by 
up to 10-fold, suggesting that it might be 
possible to develop more effective inhibitors of 
rotavirus-integrin interactions. In our 
experimental system, we also tested the in vitro 
antiviral activity of a dendrimeric peptide 
harboring multiple DGE motifs; this molecule 
displays an IC50 (3.6 µM) that is not 
significantly different from the pDGE-RGD 
IC50 (p>0.05; data not shown). Currently, no 
antivirals are commercially available for 
rotavirus. The discovery of the pDGE-RGD 
peptide may prove useful in the development of 
inhibitors of receptor recognition by rotavirus 
or other viruses that use α2β1 integrin during 
cell attachment and entry like human echovirus 
1 (61, 62).  
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FIGURE LEGENDS 
 
FIGURE 1. 2-DE map of donkey milk fat globule membrane proteins. Identified proteins are marked with 
numbers. The spots numbered 1 to 4 were excised from the gel and analyzed by MALDI-TOF MS and PMF. 
All were identified as horse milk fat globule-EGF factor 8 splice variant, also known as horse lactadherin. 
 
FIGURE 2. Amino acid sequence of the 45 kDa form of donkey lactadherin obtained by N-terminal 
sequencing, PMF by MALDI-TOF and LC-MS/MS. The sequence of the 45 kDa form of donkey lactadherin 
obtained (UniProt entry C0HJR4) is aligned with two isoforms of Equus caballus lactadherin (UniProt 
entries F7B0S3 and F5CEP2). Amino acids of the 45 kDa form of donkey lactadherin that differ from the 
other lactadherins are given in bold and underlined. 
 
FIGURE 3. Sequence alignment of the equine (EQ Lact45), bovine (BO Lactad) and human (HU Lactad) 
lactadherins. The integrin-binding motifs RGD and DGE are given in bold and boxed. 
 
FIGURE 4. Blockade of Wa infection in MA104 cells by peptides pRGD-Eq, pRGD-Hu, pRGD-Bo, pRGE 
(panel A), and pDGE-RGD, pDGE, pAGE and pDGEA (panel B). Panel C shows the blockade of Wa 
infection in MA104 cells by pDGE-RGD at different MOIs. The infectivity titer of virus in the treated 
sample is expressed as a % of the titer obtained in the absence of peptide (untreated control). Error bars 
represent the SD of the mean of 3 independent experiments. 
 
FIGURE 5. Time-of-addition experiments were performed by treating cells with pDGE-RGD for 1h before 
infection (A), for 1h during infection (B) or by adding the peptide immediately after infection (C). Control 
experiments were performed by treating cells both before and during viral adsorbtion (D). The infectivity 
titers of virus in the treated samples are expressed as a percentage of the titer obtained in the absence of 
peptide (untreated control). 
 
FIGURE 6. Effect of peptide pDGE-RGD on multiple cycles of Wa replication. Cells were treated after 
virus infection at the given peptide concentrations. The titer of rotavirus in the treated samples is expressed 
as a % of the titer in the untreated control. 
 
FIGURE 7. Evaluation of the ability of biotinylated pDGE-RGD, pDGEand pAGE to interact with the 
α2β1integrin. Experiments were performed with CHO cells expressing α2β1 (CHO-α2; panel A) and the 
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parental CHO-K1 cells lacking this integrin (panel B). Levels of peptide-cell binding are expressed in 
absorbance units (λ=405nm). Error bars represent the SD of the mean of 3 independent experiments. 
 
FIGURE 8. Evaluation of the mechanism of action of pDGE-RGD. Panel A shows the effect of pDGE-RGD 
on Wa binding to the MA104 cell surface; control experiments were performed by treating cells with pAGE-
RGE, anti-α2 antibody AK7 or anti-αvβ3 antibody LM609. On the y axis, the infectious titer of Wa bound to 
cells is expressed as a % of the titer bound to control MA104 cells in the absence of peptides or antibodies. 
Panel B shows the effect of pDGE-RGD on CRW-8 infection in MA104 cells. The infectivity titer of virus in 
the treated sample is expressed as a % of the titer obtained in the absence of peptide (untreated control). 
Panel C displays the effect of pDGE-RGD on Wa rotavirus entry into MA104 cells; the rotavirus titer 
measured in the treated samples is expressed as a % of the titer obtained in the untreated control. Evaluation 
of the virucidal effect of pDGE-RGD on infectious rotavirus particles is shown on panel D. On the y axis, the 
Wa infectious titers are expressed as focus-forming units per ml (FFU/ml). On the three graphs, error bars 
represent the SD of the mean of 3 independent experiments. 
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Spot no.
(fromFig.1)
Protein name
UniProt
KB/TrEmbl
entry
MOWSE*
Score
Experimental/nominal 
Molecular weight
(Da)
PMF
Number of signals  M/Z  
matched/number of signals 
M/Z collected–
Sequence coverage (%)
1
milk fat globule-EGF 
factor 8 splice variant
F5CEP2 5.25e+8 50,000 /43,308 24/78 - (66.2%)
2
milk fat globule-EGF 
factor 8 splice variant
F5CEP2 2.26e+9 50,000/43,308 23/59 - (61.1 %)
3
milk fat globule-EGF 
factor 8 splice variant
F5CEP2 4.74e+6 45,000/43,308 17/60 - (54.1%)
4
milk fat globule-EGF 
factor 8 splice variant
F5CEP2 1.44e+7 45,000/43,308 18/54 - (54.1%)
Table 1. 
Identification of donkey milk fat globule membrane proteins by peptide mass fingerprinting (PMF)
* Mowse score is obtained by the MS-Fit search and concerns the highest scored protein
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Spot 
number
(Fig.1)
N-terminal amino acid sequence by 
Edman degradation
Comparison with horse lactadherin 
amino acid sequence (F7B0S3)
% 
identity 
1 ASGDFCDSSQCLNGGTCLLGQ 1AIAGDFCDSSQCLNGGTCLLGQ22 95%
2 ASGDFCDSSQCLNGGTCLLGQDDL 1AIAGDFCDSSQCLNGGTCLLGQDDL25 96%
3 ASGPCFPNPCQNDGECHVIDDSHR 44GPCFPNPCQNDGECHVIDDSHR65 96%
4 ASGPCFPNPCQNDGECHVID 44GPCFPNPCQNDGECHVID62 90%
Table 2. 
N-terminal amino acid sequences and identification of donkey milk fat globule membrane proteins
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ENZYME PMF by MALDI-TOF LC-MS/MS
Position M/Z- single charge Sequence Position M/Z – charge state Sequence
Trypsin 127-134
138-144
116-126
349-357
358-367
336-345
336-345
289-300
146-157
323-335
186-198
25-37
172-185
103-115
172-185
234-248
255-277
199-224
838.4305
866.4367
1074.5902
1105.6265
1173.6660
1225.6034
1241.5983
1411.7005
1411.7328
1483.7625
1519.7620
1602.7039
1708.8727
1717.8989
1724.8676
1878.8962
2567.2161
2875.3237
GGTAEYLK
VAYSVDGR
VTGVVTQGASR
ILPVAWHNR
ITLRVELLGCam
NMFETPFLAR
NMoxFETPFLAR
DFGHIQYVAAYK
KFQFIRDAGDSK
IFPGNLDNNSHKK
LVPVACamHHGCamTLR
GDVFTQYICamSCamPR
VNMFDVPLEVQYVR
NPWIQVNLMRKMR
VNMFDVPLEVQYVR
TWGLNAFSWYPFYAR
FNAWTAQSNSASEWLQVDLGSQK
FELLGCamEVNAGCamAEPLGLEDNSIPDR
89-102
289-300
25-37
278-288
160-171
116-126
199-224
349-357
173-185
255-277
186-198
336-345
323-334
79-85
770.3600(+2)
706.2300(+2)
801.7400(+2)
558.2200(+2)
624.6400(+2)
537.7100(+2)
959.2800(+3)
553.1500(+2)
854.8500(+2)
856.5900(+3)
760.2300(+2)
613.2900(+2)
678.1600(+2)
435.6300(+2)
TGIVNAWTASNYDK
DFGHIQYVAAYK
GDVFTQYICSCPR
QVTGVVTQGAR
VFVGNVDNSGLK
VTGVVTQGASR
FELLGCEVNAGCAEPLGLEDNSIPDR
ILPVAWHNR
VNMFDVPLEVQYVR
FNAWTAQSNSASEWLQVDLGSQK
LVPVACHHGCTLR
NMFETPFLAR
IFPGNLDNNSHK
WVPELAR
Chimotrypsin 347-354
233-240
32-39
87-95
71-79
246-255
76-86
29-39
246-258
296-310
184-197
148-161
329-342
215-232
162-183
40-71
314-342
101-132
953.5931
964.4999
1012.4339
1053.5588
1157.5561
1225.6688
1267.7270
1404.6035
1596.8281
1618.7608
1618.8305
1625.8282
1708.7748
1966.9352
2453.2017
3393.4742
3393.6393
3578.8319
VRILPVAW
RTWGLNAF
ICamSCamPRGY
HRTGIVNAW
FGFMGLQRW
YARLDKQGKF
QRWVPELARL
TQYICamSCamPRGY
YARLDKQGKFNAW
VAAYKVSHSNDGANW
VRLVPVACamHHGCamTL
QFIRDAGDSKDKVF
DNNSHKKNMFETPF
GLEDNSIPDRQITASSTY
VGNVDNSGLKVNMFDVPLEVQY
TGTHCamETTCamAMPLGMETGAIADAQISASSVYF
RDQRAADSKIFPGNLDNNSHKKNMFETPF
DKNPWIQVNLMRKMRVTGVVTQGASRGGTAEY
Asp-N 155-165
166-175
1207.6317
1140.5354
DSKDKVFVGNV
DNSGLKVNMF
272-288
289-305
180-198
131-142
166-175
26-44
158-165
166-175
320-328
45-60
143-151
13-19
250-266
1-12
45-60
872.3800(+2)
968.8900(+2)
814.3400(+3)
724.3000(+2)
570.7000(+2)
774.8400(+3)
439.2100(+2)
562.6800(+2)
495.7300(+2)
842.7800(+2)
583.7300(+2)
415.1600(+2)
920.3900(+2)
674.6700(+2)
834.8300(+2)
DLGSQKQVTGVVTQGAR
DFGHIQYVAAYKVSHSN
EVQYVRLVPVACHHGCTLRF
EYLKTFKVAYSV
DNSGLKVNMoxF
DVFTQYICSCPRGYTGTHC
DKVFVGNV
DNSGLKVNMF
DSKIFPGNL
ETTCAMoxPLGMoxETGAIA
DGRKFQFIR
DGECHVI
DKQGKFNAWTAQSNSAS
ASGPCFPNPCQN
ETTCAMoxPLGMETGAIA
Table 3.
Identification of the 45 kDa donkeylactadherin short form by enzymatic digestions and mass spectrometry techniques
Cam: carbamidomethylated cysteine; Mox: oxidized methionine.
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PEPTIDES Features
IC50
(µM)
95% 
Confidence 
Interval
CC50
(µM)
SI
pDGE peptide DGE, 8 AA, equine 17.3 6.9 - 43.5 >880 >50.9
pAGE AA substitution in position 3 256.6 177.7 - 370.3 >880 >3.4
pDGE-RGD Wild type peptide 4.4 2.7 - 7.1 >880 >200
pAGE-RGD AA substitution in position 3 > 220 n.a. >880 >4
pDGE-RGE AA substitution in position 16 > 220 n.a. >880 >4
pAGE-RGE
AA substitutions in position
3 and 16
> 220 n.a.* >880 >4
pDGE-RGDmut1 AA substitution in position 1 13.5 5.1 - 35.7 >880 >65.2
pDGE-RGDmut2 AA substitution in position 13 13.1 7.5 - 22.9 >880 >67.2
pDGE-RGDmut3 AA substitution in position 19 6.7 2.2 - 20.4 >880 >131.3
Table 4. 
Effect of lactadherin-derived peptides on cell viability and Wa rotavirus infectivity in MA104 cells
*n.a.: not assessable
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Table 5.
Effect of lactadherin-derived peptides on cell viability and Wa rotavirus infectivity in Caco-2 cells
PEPTIDES Features
IC50
(µM)
95% 
Confidence 
Interval
CC50
(µM)
SI
pDGE-RGD Wild type peptide 8.8 6.1 - 12.5 945.1 102.7
pDGE-RGE AA substitution in position 16 46.0 24.9 - 84.9 >880 19.1
pAGE-RGD AA substitution in position 3 101.7 78.6 - 131.6 >880 8.7
pAGE-RGE
AA substitutions in position
3 and 16
152.5 123.3 - 188.6 >880 5.8
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Figure 1 
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Figure 2 
 
 
F7B0S3 1AIAGDFCDSSQCLNGGTCLLGQDDLPFYCLCPEGFTGLICNETEKGPCFPNPCQNDGECHVIDDSHRGDVFTQYIC 
F5CEP2      1GRPPFYCLCPEGFTGLICNETEKGPCFPNPCQNDGECHVIDDSHRGDVFTQYIC 
C0HJR4                 1ASGPCFPNPCQNDGECHVIDDSHRGDVFTQYIC 
 
F7B0S3 77SCPRGYTGTHCETTCAMPLGMETGAIADAQISASSVYFGFMGLQRWVPELARLHRTGIVNAWTASNYDKNPWIQ 
F5CEP2 55SCPRGYTGTHCETTCAMPLGMETGAIADAQISASSVYFGFMGLQRWVPELARLHRTGIVNAWTASNYDKNPWIQ 
C0HJR4 34SCPRGYTGTHCETTCAMPLGMETGAIADAQISASSVYFGFMGLQRWVPELARLHRTGIVNAWTASNYDKNPWIQ 
 
F7B0S3 151VNLMRKMRVTGVVTQGASRGGTAEYLKTFKVAYSVDGRKFQFIRDAGDSKDKVFVGNVDNSGLKVNMFDVPLE 
F5CEP2 129VNLMRKMRVTGVVTQGASRGGTAEYLKTFKVAYSVDGRKFQFIRDAGDSKDKVFVGNVDNSGLKVNMFDVPLE 
C0HJR4 108VNLMRKMRVTGVVTQGASRGGTAEYLKTFKVAYSVDGRKFQFIRDAGDSKDKVFVGNVDNSGLKVNMFDVPLE 
 
F7B0S3  224VQYVRLVPVACHHGCTLRFELLGCEVN -GCAEPLGLEDNSIPDRQITASSTYRTWGLNAFSWYPFYARLDKQGKFN 
F5CEP2 202VQYVRLVPVACHHGCTLRFELLGCEVNAGCAEPLGLEDNSIPDRQITASSTYRTWGLNAFSWYPFYARLDKQGKFN 
C0HJR4  181VQYVRLVPVACHHGCTLRFELLGCEVNAGCAEPLGLEDNSIPDRQITASSTYRTWGLNAFSWYPFYARLDKQGKFN 
 
F7B0S3 298AWTAQSNSASEWLQVDLGSQKQVTGVITQGARDFGHIQYVAAYKVSHSNDGANWTEYRDQRAADSKIFPGNLDNN 
F5CEP2 277AWTAQSNSASEWLQVDLGSQKQVTGVITQGARDFGHIQYVAAYKVSHSNDGANWTEYRDQRAADSKIFPGNLDNN 
C0HJR4 256AWTAQSNSASEWLQVDLGSQKQVTGVVTQGARDFGHIQYVAAYKVSHSNDGANWXXRDQRAADSKIFPGNLDNN 
 
F7B0S3 373SHKKNMFETPFLARFVRILPVAWHNRITLRVELLGC409 
F5CEP2 352SHKKNMFETPFLARFVRILPVAWHNRITLRVELLGC388 
C0HJR4  292SHKKNMFETPFLARXVRILPVAWHNRITLRVELLGC328 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
 
 
30 100 300
0
50
100
pDGE-RGD concentration (M)
T
it
e
r 
o
f 
in
fe
c
ti
o
u
s
 W
a
(%
 o
f 
c
o
n
tr
o
l)
Equine Lactadherin Peptides Inhibit Human Rotavirus Infection 
 
29 
 
Figure 7 
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Figure 8 
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